Protein Degraders and Molecular Glues: First Approvals and Open Questions | Oncology Modality Intelligence | US, EU5, Japan & China

PUBLISHED: August 21, 2026

PAGES: 120 Pages

DELIVERY TIME: 7-10 business days

ADD TO COMPARE

SELECT AN OPTION

Targeted protein degradation has crossed the line that separates a platform story from a drug class. Vepdegestrant - the estrogen-receptor PROTAC built by Arvinas with Pfizer - became the first degrader approved by the FDA in May 2026, converting two decades of ubiquitin-proteasome chemistry into a regulatory precedent that every company in the field will now cite. The class arrives with real momentum and real questions. The momentum is visible in the breadth of the pipeline: Bristol Myers Squibb's CELMoD molecular glues iberdomide and mezigdomide carry the Revlimid succession in myeloma; Kymera has moved beyond oncology into STAT6 and IRAK4 immunology programs; Nurix, C4 Therapeutics, and Monte Rosa have each placed degraders with major partners, including Gilead, Roche, Sanofi, and Novartis; BeiGene's BTK degrader is heading toward an accelerated-approval filing; and Hinova leads the Chinese field. The questions are just as concrete. Resistance biology is only beginning to be mapped; degradation-specific biomarkers remain immature compared with the target-engagement tools of inhibition; dose optimization for catalytic degraders defies habits formed on stoichiometric inhibitors; and no payer has yet priced the modality's particular pattern of benefit. Japan holds more of this story than outsiders assume: Eisai's E7820 was among the earliest molecular glues in the clinic, Astellas built the first-in-class KRAS G12D degrader ASP3082, Takeda maintains degrader discovery collaborations, and FIMECS represents Japan's platform biotech layer. This report maps the science - PROTACs, molecular glues, and the degraders in between - the approval precedent and what it establishes, the pipeline by target and partner, the Japanese programs in detail, the biomarker and resistance research frontier, and the commercialization questions Pfizer and its peers now face. It serves oncology business-development teams evaluating degrader assets, platform investors pricing the class after its first approval, and Japanese stakeholders positioning domestic programs within the global race.

Scope and Coverage

The report covers degrader mechanisms and platform design, the vepdegestrant approval precedent, the global pipeline across oncology and immunology targets, Japanese programs from Astellas, Eisai, Takeda, and FIMECS, biomarker and resistance questions, and pricing considerations for the new modality.

Report Highlights

Vepdegestrant (VEPPANU): the first PROTAC approval (2026) and the precedent it sets
CELMoD succession: iberdomide and mezigdomide in the post-Revlimid myeloma landscape
Kymera, Nurix, C4, and Monte Rosa: partnered programs with Gilead, Sanofi, Roche, and Novartis
Japanese positions: Astellas ASP3082, Eisai E7820, Takeda collaborations, and FIMECS
BeiGene BGB-16673 and the BTK-degrader race toward accelerated approval
Open questions: resistance biology, degradation biomarkers, and modality pricing

Product Code: JPH-108

Table of Content

1. Executive Summary

2. Protein Degraders and Molecular Glues: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Arvinas (US) - vepdegestrant (VEPPANU), the first PROTAC approved by the FDA (May 2026)
Pfizer (US) - vepdegestrant co-developer; commercialization partner search under way
Bristol Myers Squibb (US) - iberdomide and mezigdomide CELMoD molecular glues for the Revlimid succession
Kymera (US) - KT-621 STAT6 and KT-474 IRAK4 (with Sanofi); Gilead CDK2 degrader deal (Jun 2025)
C4 Therapeutics (US) - cemsidomide (CFT7455) IKZF1/3 degrader in myeloma
Nurix (US) - bexobrutideg (NX-5948) BTK degrader with Gilead, Sanofi, and Seagen collaborations
Monte Rosa Therapeutics (US) - MRT-2359 GSPT1 (Roche partner) and MRT-8102 NEK7 (Novartis collaboration, 2025)
Astellas (JP) - ASP3082 KRAS G12D degrader, a first-in-class degrader effort from Japan
Eisai (JP) - E7820 RBM39 molecular glue; aryl sulfonamide class originator
Takeda (JP) - degrader and molecular-glue discovery collaborations in oncology
BeiGene (CN) - BGB-16673 BTK CDAC; accelerated-approval submission planned in CLL (2026)
Hinova (CN) - HP518 androgen-receptor degrader; China degrader front-runner
FIMECS (JP) - Japanese RaPID-based degrader biotech

Product Code: JPH-108

List of Tables

Table 1. Targeted protein degradation primer: PROTACs, molecular glues, and the ubiquitin system
Table 2. Vepdegestrant (VEPPANU) development history and the 2026 FDA approval
Table 3. VERITAC program structure behind the vepdegestrant package
Table 4. Arvinas-Pfizer collaboration structure and the commercialization-partner search
Table 5. Iberdomide and mezigdomide: CELMoD positioning in the Revlimid succession
Table 6. Bristol Myers Squibb molecular-glue platform and myeloma franchise strategy
Table 7. Kymera KT-621 (STAT6) and KT-474 (IRAK4, with Sanofi): immunology expansion
Table 8. Kymera-Gilead CDK2 degrader collaboration (2025)
Table 9. C4 Therapeutics cemsidomide (CFT7455) IKZF1/3 degrader in myeloma
Table 10. Nurix bexobrutideg (NX-5948) BTK degrader and the Gilead, Sanofi, and Seagen collaborations
Table 11. Monte Rosa MRT-2359 (GSPT1) with Roche and MRT-8102 (NEK7) with Novartis (2025)
Table 12. BeiGene BGB-16673 BTK CDAC and the planned CLL accelerated-approval submission (2026)
Table 13. Hinova HP518 androgen-receptor degrader and the Chinese degrader field
Table 14. Astellas ASP3082: the first-in-class KRAS G12D degrader from Japan
Table 15. Eisai E7820 RBM39 molecular glue and the aryl sulfonamide lineage
Table 16. Takeda degrader and molecular-glue discovery collaborations
Table 17. FIMECS RaPID-based degrader discovery platform
Table 18. E3-ligase toolbox: cereblon, VHL, and the search for new recruiters
Table 19. Degradation-versus-inhibition pharmacology and its clinical implications
Table 20. Resistance mechanisms to degraders: ligase-pathway and target adaptations
Table 21. Degradation biomarkers: DC50 concepts, ternary-complex assays, and PD readouts
Table 22. Dose-optimization practice for catalytic degraders under modern frameworks
Table 23. Estrogen-receptor degradation context: the SERD competitive landscape
Table 24. BTK degradation versus covalent inhibition in the CLL treatment sequence
Table 25. Immunology expansion of the degrader modality beyond oncology
Table 26. Neurology and other frontier indications for degrader chemistry
Table 27. CMC and oral-exposure engineering for heterobifunctional molecules
Table 28. PMDA review considerations for a first degrader filing in Japan
Table 29. Japan trial participation across global degrader programs
Table 30. Companion-diagnostic and biomarker-testing requirements for degrader programs
Table 31. Deal and partnership activity in targeted protein degradation, 2023-2026
Table 32. Deal-term benchmarks for degrader platform licenses
Table 33. Competitive-position matrix of clinical-stage degraders by target
Table 34. Scenario grid for the estrogen-receptor degrader market after approval
Table 35. Scenario grid for molecular-glue succession in myeloma
Table 36. Scenario grid for Japanese degrader programs reaching global filings
Table 37. NHI pricing questions for a first-in-class modality
Table 38. Risk register for degrader-platform investors
Table 39. Risk register for incumbents whose franchises face degrader competition
Table 40. Key opinion leader landscape in degrader-relevant Japanese specialties
Table 41. Discovery-screening infrastructure requirements for glue and PROTAC programs
Table 42. Watchlist of degrader readouts, filings, and deals, 2026-2028
Table 43. Stakeholder map: platform companies, partners, regulators, and payers
Table 44. Technology-assessment framework for degrader platforms
Table 45. Historical lessons from the IMiD lineage for glue development
Table 46. Partnering-question checklist for Japanese companies evaluating degrader assets
Table 47. Framework for valuing platform-stage degrader companies post-approval-precedent
Table 48. Implications of the vepdegestrant precedent for regulatory strategy globally
Table 49. Key-question tree for oncology BD teams in the degrader class
Table 50. Timeline of targeted protein degradation from concept to approval, 2013-2026